Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) insider Joseph P. Lyssikatos sold 12,000 shares of the stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $22.49, for a total transaction of $269,880.00. Following the transaction, the insider now directly owns 1,077,936 shares in the company, valued at $24,242,780.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Enliven Therapeutics Stock Down 2.1 %
ELVN opened at $21.74 on Thursday. The stock’s 50 day moving average price is $23.14 and its two-hundred day moving average price is $20.72. The firm has a market capitalization of $1.02 billion, a P/E ratio of -11.26 and a beta of 1.09. Enliven Therapeutics, Inc. has a 12-month low of $9.80 and a 12-month high of $27.67.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.17. As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -2.02 earnings per share for the current year.
Analysts Set New Price Targets
Read Our Latest Research Report on Enliven Therapeutics
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in ELVN. The Manufacturers Life Insurance Company acquired a new stake in Enliven Therapeutics during the second quarter worth about $322,000. Marshall Wace LLP bought a new stake in shares of Enliven Therapeutics in the 2nd quarter worth approximately $4,489,000. First Turn Management LLC acquired a new stake in shares of Enliven Therapeutics during the 2nd quarter worth approximately $9,657,000. Nicholas Investment Partners LP bought a new stake in shares of Enliven Therapeutics during the second quarter valued at approximately $1,310,000. Finally, American Century Companies Inc. raised its stake in shares of Enliven Therapeutics by 44.7% in the second quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after purchasing an additional 8,540 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.
About Enliven Therapeutics
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Stories
- Five stocks we like better than Enliven Therapeutics
- What is a Death Cross in Stocks?
- Why Dick’s Could Be a Slam Dunk for Your Investment Portfolio
- ETF Screener: Uses and Step-by-Step Guide
- Introduction to Fibonacci Retracement Levels
- Consumer Staples Stocks, Explained
- Top 3 Stocks to Outperform the S&P 500 in a Downturn
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.